Clinical Trial: A Study to Assess the Safety of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis

U.S., June 2 -- ClinicalTrials.gov registry received information related to the study (NCT07616375) titled 'A Study to Assess the Safety of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis' on May 23.

Brief Summary: This is a phase III, single-arm, open-label, multicenter study to assess the safety of HSK31858 in non-cystic fibrosis bronchiectasis (NCFBE) participants.

Study Start Date: Sept. 28, 2025

Study Type: INTERVENTIONAL

Condition: Non-cystic Fibrosis Bronchiectasis

Intervention: DRUG: HSK31858, tablet

HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 52-week treatment period in patients with non-cystic fibrosis bronchiectasis

Recruitment Sta...